Based on the Guerbet SA stock forecast from 0 analysts, the average analyst target price for Guerbet SA is not available over the next 12 months. Guerbet SA’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Guerbet SA is Neutral, which is based on 6 positive signals and 7 negative signals. At the last closing, Guerbet SA’s stock price was EUR 24.25. Guerbet SA’s stock price has changed by -4.72% over the past week, -17.94% over the past month and +30.80% over the last year.
No recent analyst target price found for Guerbet SA
No recent average analyst rating found for Guerbet SA
Company Overview Guerbet SA
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. Guerbet SA was incorporated in 1926 and is headquartered in Villepinte, France. Read Less
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate...Read More
Frequently Asked Questions About Guerbet SA (4G8:F) Stock
Stock Target Advisor's fundamental analysis for Guerbet SA's stock is Neutral.
4G8:F stock's dividend yield is 2.02%.
Our analysis grades 4G8:F stock's dividend yield at D+. This means that 4G8:F stock's dividend yield is above 67% of the stocks in the Medical Devices sector in the F exchange.
Based on this 4G8:F may be a average dividend stock for its sector.
Unfortunately we do not have enough data on 4G8:F's stock to indicate what its average analyst target is.
4G8:F stock's Price/Earning ratio is 10.04.
Our analysis grades 4G8:F stock's Price / Earning ratio at A-. This means that 4G8:F stock's Price/Earning ratio is above 8.999999999999996% of the stocks in the Medical Devices sector in the F exchange.
Based on this 4G8:F may be undervalued for its sector.
The last closing price of 4G8:F's stock was EUR 24.25.
The most recent market capitalization for 4G8:F is EUR 0.32B.
Unfortunately we do not have enough analyst data on 4G8:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Guerbet SA's stock.
As per our most recent records Guerbet SA has 2,920 Employees.
Guerbet SA's registered address is 15, rue des Vanesses, Villepinte, France, 93420.
You can get more information about it from Guerbet SA's website at https://www.guerbet.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Guerbet SA (4G8:F) Stock
Stock Target Advisor's fundamental analysis for Guerbet SA's stock is Neutral.
4G8:F stock's dividend yield is 2.02%.
Our analysis grades 4G8:F stock's dividend yield at D+. This means that 4G8:F stock's dividend yield is above 67% of the stocks in the Medical Devices sector in the F exchange.
Based on this 4G8:F may be a average dividend stock for its sector.
Unfortunately we do not have enough data on 4G8:F's stock to indicate what its average analyst target is.
4G8:F stock's Price/Earning ratio is 10.04.
Our analysis grades 4G8:F stock's Price / Earning ratio at A-. This means that 4G8:F stock's Price/Earning ratio is above 8.999999999999996% of the stocks in the Medical Devices sector in the F exchange.
Based on this 4G8:F may be undervalued for its sector.
The last closing price of 4G8:F's stock was EUR 24.25.
The most recent market capitalization for 4G8:F is EUR 0.32B.
Unfortunately we do not have enough analyst data on 4G8:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Guerbet SA's stock.
As per our most recent records Guerbet SA has 2,920 Employees.
Guerbet SA's registered address is 15, rue des Vanesses, Villepinte, France, 93420.
You can get more information about it from Guerbet SA's website at https://www.guerbet.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4G8:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
